Artelo Files S-1 for Resale of 899,972 Shares; Cancer Drug Shows Promise

TL;DR

**ARTL's S-1 for warrant and note resales is a red flag for dilution, despite promising interim clinical data for ART27.13 and ART26.12, making it a speculative buy at best.**

AI Summary

Artelo Biosciences, Inc. (ARTL) is a clinical-stage biopharmaceutical company focused on lipid-signaling modulation pathways. The company is offering to resell up to 899,972 shares of common stock, consisting of 215,292 shares from convertible notes, 246,498 shares from warrants at $6.24 per share, and 438,182 shares from warrants at $3.40 per share. ARTL will not receive any proceeds from these sales by the Selling Securityholders, but will receive proceeds from any cash exercise of warrants. The company's lead candidate, ART27.13, a dual cannabinoid agonist for cancer-related anorexia, showed compelling interim Phase 2a results as of September 3, 2025, with patients titrating to 1300 micrograms experiencing a mean body weight increase of 6.38% compared to a 5.42% loss in placebo, and a 4.23% increase in lean body mass. ART26.12, an FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, completed Phase 1 enrollment in April 2025, with favorable safety and dose-dependent absorption results announced in June 2025. The company also completed a 1-for-6 reverse stock split on June 13, 2025, and its stock traded at $1.85 per share on November 14, 2025.

Why It Matters

This S-1 filing signals a potential dilution event for existing ARTL investors as up to 899,972 shares from convertible notes and warrants could enter the market, though the company itself won't receive direct proceeds from these resales. For employees and customers, the continued development of ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy offers hope for new treatments in areas of significant unmet medical need. The positive interim Phase 2a data for ART27.13, showing a 6.38% mean body weight increase, could enhance ARTL's competitive position against other biotechs targeting cachexia, while the successful Phase 1 for ART26.12 positions it in the competitive pain management and oncology support markets.

Risk Assessment

Risk Level: high — The filing explicitly states, 'Investing in our securities involves a high degree of risk.' This is evidenced by the nature of the offering, which is a resale of up to 899,972 shares by Selling Securityholders, meaning the company will not receive any direct proceeds from these sales, limiting its immediate capital infusion. Furthermore, as a clinical-stage biopharmaceutical company, ARTL faces inherent risks associated with drug development, including regulatory hurdles and trial outcomes, despite positive interim Phase 2a results for ART27.13 and Phase 1 results for ART26.12.

Analyst Insight

Investors should exercise caution due to potential dilution from the resale of 899,972 shares and the company's lack of direct proceeds from this offering. While the positive interim clinical data for ART27.13 and ART26.12 are encouraging, the high-risk nature of clinical-stage biopharma investments warrants a thorough review of the full 'Risk Factors' section before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$10.1 million

total Debt

$0

net Income

-$12.5 million

eps

N/A

gross Margin

N/A

cash Position

$1.1 million

revenue Growth

N/A

Key Numbers

• 899,972 — Shares of Common Stock (Total shares offered for resale by Selling Securityholders)
• 215,292 — Shares of Common Stock (Issuable upon conversion of convertible notes)
• 246,498 — Shares of Common Stock (Issuable upon exercise of warrants at $6.24 per share)
• 438,182 — Shares of Common Stock (Issuable upon exercise of warrants at $3.40 per share)
• $1.85 — Last reported sales price (ARTL Common Stock on November 14, 2025)
• 1-for-6 — Reverse stock split ratio (Effected on June 13, 2025)
• 6.38% — Mean body weight increase (In ART27.13 treatment group (n=5) in Phase 2a CAReS trial, compared to -5.42% loss in placebo (n=6))
• 4.23% — Lean body mass increase (In ART27.13 treatment group at one month, compared to -3.15% loss in placebo)
• 32 — Participants enrolled (In CAReS Phase 2 trial as of June 30, 2025)
• 49 — Subjects enrolled (In ART26.12 Phase 1 Single Ascending Dose study)

Key Players & Entities

• ARTELO BIOSCIENCES, INC. (company) — Registrant in S-1 filing
• Gregory D. Gorgas (person) — Chief Executive Officer and President
• Martin J. Waters (person) — Counsel at Wilson Sonsini Goodrich & Rosati, P.C.
• Robert L. Wernli, Jr. (person) — Counsel at Wilson Sonsini Goodrich & Rosati, P.C.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq Capital Market (company) — Stock exchange for ARTL
• AstraZeneca plc (company) — Original inventor of ART27.13
• NEOMED Institute (company) — Licensed ART27.13 from AstraZeneca, renamed adMare Bioinnovations
• Stony Brook University (company) — Licensed FABP5 inhibitors to Artelo
• U.S. Food & Drug Administration (regulator) — Granted IND clearance for ART26.12

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company has a history of net losses and an accumulated deficit of $120.9 million as of September 30, 2025. It anticipates significant future expenses for research and development, clinical trials, and commercialization. Without additional financing, the company may not be able to continue its operations.
• Uncertainty of Drug Approval [high — regulatory]: The development of ART27.13 and ART26.12 is subject to rigorous regulatory review by the FDA and other global health authorities. There is no guarantee that these drug candidates will successfully complete clinical trials or receive marketing approval, which could materially impact the company's future prospects.
• Competition in Oncology and Neuropathy Markets [medium — market]: The company operates in highly competitive markets for cancer-related anorexia and chemotherapy-induced peripheral neuropathy. Existing treatments and new entrants pose significant competition, and the company's success depends on demonstrating superior efficacy and safety profiles for its drug candidates.
• Reliance on Key Personnel [medium — operational]: The success of Artelo Biosciences is heavily dependent on its management team and scientific advisors. The loss of key personnel could disrupt research, development, and strategic operations, potentially hindering the company's ability to advance its pipeline.
• Dilution from Stock Issuances [medium — financial]: The company has issued and may continue to issue shares of common stock, including upon conversion of convertible notes and exercise of warrants. This can lead to significant dilution for existing shareholders, impacting the value of their holdings.

Industry Context

Artelo Biosciences operates in the highly competitive biopharmaceutical sector, specifically targeting oncology supportive care and neurological disorders. The market for cancer-related anorexia treatments is growing due to increasing cancer diagnoses and the need for improved patient quality of life. The peripheral neuropathy market, particularly for chemotherapy-induced cases, also presents an unmet medical need. Key trends include the development of targeted therapies and the increasing focus on patient-reported outcomes.

Regulatory Implications

The company's drug candidates, ART27.13 and ART26.12, must navigate the stringent regulatory pathways of agencies like the FDA. Successful clinical trials demonstrating safety and efficacy are paramount for obtaining marketing approval. Any delays or failures in these trials pose significant risks to the company's future commercialization efforts and financial viability.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for ART27.13 and ART26.12.
2. Assess the company's ability to secure future funding.
3. Evaluate the competitive landscape and Artelo's differentiation.
4. Consider the impact of the recent reverse stock split and potential future dilution.

Key Dates

• 2025-09-03: Interim Phase 2a results for ART27.13 announced — Showed compelling positive results for body weight and lean body mass increase, supporting the potential of the drug candidate.
• 2025-06-13: 1-for-6 reverse stock split effected — Aimed to increase the per-share market price of common stock, potentially making it more attractive to institutional investors and meeting exchange listing requirements.
• 2025-06-01: Favorable safety and dose-dependent absorption results for ART26.12 Phase 1 announced — Indicates positive early-stage development for the FABP5 inhibitor candidate.
• 2025-04-01: Phase 1 enrollment completed for ART26.12 — Reached a key milestone in the development of the second drug candidate.
• 2025-11-14: ARTL Common Stock last reported sales price — Indicates current market valuation of the company's stock.

Glossary

Lipid-Signaling Modulation Pathways

Biological pathways involving lipids (fats) that regulate cellular processes. Modulating these pathways can be a therapeutic strategy. (This is the core scientific focus of Artelo Biosciences' drug development.)

Cannabinoid Agonist

A substance that activates cannabinoid receptors in the body, mimicking the effects of compounds like THC or CBD. (ART27.13 is a dual cannabinoid agonist, targeting specific receptors for therapeutic effect.)

FABP5 Inhibitor

A molecule that blocks the activity of Fatty Acid Binding Protein 5, an enzyme involved in various cellular processes, including inflammation and cell growth. (ART26.12 is an FABP5 inhibitor, targeting a specific mechanism for treating neuropathy.)

Clinical-Stage Biopharmaceutical Company

A company focused on developing drugs that are currently undergoing testing in human clinical trials. (Artelo is in the development phase, meaning its products are not yet approved for sale.)

Reverse Stock Split

A corporate action where a company reduces the number of outstanding shares by consolidating them, typically to increase the per-share price. (Artelo recently underwent a 1-for-6 reverse stock split, impacting share count and price.)

Year-Over-Year Comparison

This S-1 filing provides an update on Artelo Biosciences' progress since its previous filings. Key developments include the announcement of compelling interim Phase 2a results for ART27.13, demonstrating significant body weight and lean body mass increases, and the completion of Phase 1 enrollment for ART26.12 with favorable safety data. The company also executed a 1-for-6 reverse stock split to improve its stock price. However, the company continues to operate at a net loss, with an accumulated deficit of $120.9 million as of September 30, 2025, and a cash position of $1.1 million, highlighting its ongoing need for financing.

Key Financial Figures

• $0.001 — 9,972 shares of common stock, par value $0.001 per share ("Common Stock"), of Artelo B
• $6.24 — ise of warrants at an exercise price of $6.24 per share (the "$6.24 Warrants"), and (
• $3.40 — ise of warrants at an exercise price of $3.40 per share (the "$3.40 Warrants"). The $
• $1.85 — f Common Stock on November 14, 2025 was $1.85 per share. i On June 11, 2025, we fi
• $8.0 million — er isoforms. SBU received approximately $8.0 million in funding from the National Institutes
• $4.2 million — FABP5 inhibitor candidates including a $4.2 million grant in 2020 to advance research of FA

Filing Documents

• artl_s1.htm (S-1) — 507KB
• artl_ex33.htm (EX-3.3) — 28KB
• artl_ex51.htm (EX-5.1) — 22KB
• artl_ex232.htm (EX-23.2) — 2KB
• artl_ex107.htm (EX-FILING FEES) — 20KB
• artl_ex51img1.jpg (GRAPHIC) — 2KB
• artl_s1img2.jpg (GRAPHIC) — 8KB
• artl_s1img1.jpg (GRAPHIC) — 8KB
• artl_ex51img3.jpg (GRAPHIC) — 1KB
• artl_ex33img36.jpg (GRAPHIC) — 2KB
• artl_ex33img40.jpg (GRAPHIC) — 22KB
• artl_ex33img41.jpg (GRAPHIC) — 4KB
• artl_ex33img42.jpg (GRAPHIC) — 4KB
• artl_ex51img2.jpg (GRAPHIC) — 1KB
• 0001640334-25-002154.txt ( ) — 963KB
• artl-20251117.xsd (EX-101.SCH) — 5KB
• artl-20251117_lab.xml (EX-101.LAB) — 10KB
• artl-20251117_cal.xml (EX-101.CAL) — 1KB
• artl-20251117_pre.xml (EX-101.PRE) — 6KB
• artl-20251117_def.xml (EX-101.DEF) — 2KB
• artl_s1_htm.xml (XML) — 3KB
• artl_ex107_htm.xml (XML) — 8KB

RISK FACTORS

RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 13

USE OF PROCEEDS

USE OF PROCEEDS 14 DIVIDEND POLICY 15 SELLING SECURITYHOLDERS 16 PLAN OF DISTRIBUTION 19 PRINCIPAL STOCKHOLDERS 21

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 23 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 26 LEGAL MATTERS 31 EXPERTS 31 WHERE YOU CAN FIND MORE INFORMATION 31 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 32 iii Table of Contents ABOUT THIS PROSPECTUS As used in this prospectus, unless the context otherwise requires or indicates, references to "the Company," "we," "our," "ourselves," "us" and "Artelo" refer to Artelo Biosciences, Inc. This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the "SEC"), under which the Selling Securityholders may, from time to time, sell the securities described in this prospectus in one or more offerings or otherwise described under " Plan of Distribution ." We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. Such prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the headings " Where You Can Find More Information " and " Incorporation by Reference ." Neither we, nor the Selling Securityholders, have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you.

View Full Filing

View this S-1 filing on SEC EDGAR